CDX-1/CDX-2 Expression Is a Favorable Prognostic Factor in Epstein-Barr Virus-Negative, Mismatch Repair-Proficient Advanced Gastric Cancers
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Caudal type homeobox (CDX)-1 and -2 are reportedly involved in the development and progression of gastric cancer (GC). Although there are several reports on the prognostic significance of CDX-2 expression in GC, it remains controversial. In this study, we sought to validate the prognostic value of CDX-1 and -2 expression according to the histologic and molecular subtypes of GC. Methods: In total, 1,158 cases of advanced GC were investigated using immunohistochemical staining and tissue microarrays for CDX-1 and -2 expression, and survival analysis was performed according to different histological and molecular subtypes. Results: Of the 915 GCs with CDX-1 expression, 163 (17.8%) were Epstein-Barr virus (EBV)- positive or mismatch repair deficient (MMR-d), and the remaining 752 (82.2%) were EBV-negative or MMR-proficient (MMR-p). Of the 1,008 GCs with CDX-2 expression, 177 (17.5%) were EBV-positive or MMR-d, and the remaining 831 (82.5%) were EBV-negative or MMR-p. In the EBV-positive and MMR-d groups, CDX expression had no relationship with patient outcomes. In the EBV-negative and MMR-p groups, 404 (53.7%) and 523 (62.9%) samples were positive for CDX-1 and CDX-2 expression, respectively. Survival analysis demonstrated that CDX-1 and CDX-2 expression in all patients was correlated with favorable outcomes in terms of overall survival (multivariate analysis; p=0.018 and p=0.028, respectively). In the subgroup analysis, CDX-1 expression and CDX-2 expression were associated with favorable outcomes in EBV-negative and MMR-p intestinal (p=0.015 and p=0.010), and mixed and diffuse-type (p=0.019 and p=0.042) GCs, respectively. Conclusions: The expression of CDX-1 and CDX-2 is a favorable prognostic factor in EBVnegative, MMR-p advanced GC.
Abstract
Background/Aims: Caudal type homeobox (CDX)-1 and -2 are reportedly involved in the development and progression of gastric cancer (GC). Although there are several reports on the prognostic significance of CDX-2 expression in GC, it remains controversial. In this study, we sought to validate the prognostic value of CDX-1 and -2 expression according to the histologic and molecular subtypes of GC. Methods: In total, 1,158 cases of advanced GC were investigated using immunohistochemical staining and tissue microarrays for CDX-1 and -2 expression, and survival analysis was performed according to different histological and molecular subtypes. Results: Of the 915 GCs with CDX-1 expression, 163 (17.8%) were Epstein-Barr virus (EBV)- positive or mismatch repair deficient (MMR-d), and the remaining 752 (82.2%) were EBV-negative or MMR-proficient (MMR-p). Of the 1,008 GCs with CDX-2 expression, 177 (17.5%) were EBV-positive or MMR-d, and the remaining 831 (82.5%) were EBV-negative or MMR-p. In the EBV-positive and MMR-d groups, CDX expression had no relationship with patient outcomes. In the EBV-negative and MMR-p groups, 404 (53.7%) and 523 (62.9%) samples were positive for CDX-1 and CDX-2 expression, respectively. Survival analysis demonstrated that CDX-1 and CDX-2 expression in all patients was correlated with favorable outcomes in terms of overall survival (multivariate analysis; p=0.018 and p=0.028, respectively). In the subgroup analysis, CDX-1 expression and CDX-2 expression were associated with favorable outcomes in EBV-negative and MMR-p intestinal (p=0.015 and p=0.010), and mixed and diffuse-type (p=0.019 and p=0.042) GCs, respectively. Conclusions: The expression of CDX-1 and CDX-2 is a favorable prognostic factor in EBVnegative, MMR-p advanced GC.
참고문헌 (21)
- Silberg DG, "Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice", Gastroenterology, 122, pp.689~696 (2002)
- Mutoh H, "Cdx1 induced intestinal metaplasia in the transgenic mouse stomach : comparative study with Cdx2 transgenic mice", Gut, 53, pp.1416~1423 (2004)
- Byoung Hwan Lee, "The Role of CDX2 in Intestinal Metaplasia Evaluated Using Immunohistochemistry", Gut and Liver, 6(1), pp.71~77 (2012), 거트앤리버 소화기연관학회협의회
- Wang XT, "Prognostic significance of Cdx2 immunohistochemical expression in gastric cancer: a meta-analysis of published literatures", J Exp Clin Cancer Res, 31, pp.98~ (2012)
- Choi SI, "CDX1 expression induced by CagA-expressing Helicobacter pylori promotes gastric tumorigenesis", Mol Cancer Res, 17, pp.2169~2183 (2019)
- Almeida R, "Expression of intestine-specific transcription factors, CDX1 and CDX2, in intestinal metaplasia and gastric carcinomas", J Pathol, 199, pp.36~40 (2003)
- Park DY, "CDX2 expression in the intestinal-type gastric epithelial neoplasia : frequency and significance", Mod Pathol, 23, pp.54~61 (2010)
- Xie Y, "Overexpression of Cdx2 inhibits progression of gastric cancer in vitro", Int J Oncol, 36, pp.509~516 (2010)
- Qin R, "Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions", World J Gastroenterol, 18, pp.3296~3302 (2012)
- Ru Y, "Detection and clinical significance of lymph node micrometastasis in gastric cardia adenocarcinoma", J Int Med Res, 40, pp.293~299 (2012)
- Ge J, "A clinicopathological study on the expression of cadherin-17 and caudalrelated homeobox transcription factor(CDX2)in human gastric carcinoma", Clin Oncol(R Coll Radiol), 20, pp.275~283 (2008)
- Roessler K, "Co-expression of CDX2 and MUC2 in gastric carcinomas : correlations with clinico-pathological parameters and prognosis", World J Gastroenterol, 11, pp.3182~3188 (2005)
- Xiao ZY, "Expression of CDX2 and villin in gastric cardiac intestinal metaplasia and the relation with gastric cardiac carcinogenesis", Asian Pac J Cancer Prev, 13, pp.247~250 (2012)
- Young Hoon Youn, "Long Noncoding RNA N-BLR Upregulates the Migration and Invasion of Gastric Adenocarcinoma", Gut and Liver, 13(4), pp.421~429 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- 배윤성, "Usefulness of Immunohistochemistry for Microsatellite Instability Screening in Gastric Cancer", Gut and Liver, 9(5), pp.629~635 (2015), 거트앤리버 소화기연관학회협의회
- Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
- Cheong JH, "Predictive test for chemotherapy response in resectable gastric cancer : a multicohort, retrospective analysis", Lancet Oncol, 19, pp.629~638 (2018)
- Park CK, "Receptor tyrosine kinase amplified gastric cancer : clinicopathologic characteristics and proposed screening algorithm", Oncotarget, 7, pp.72099~72112 (2016)
- Robert J. Huang, "Diagnosis and Management of Gastric Intestinal Metaplasia: Current Status and Future Directions", Gut and Liver, 13(6), pp.596~603 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Joo Ha Hwang, "Understanding Gastric Cancer Risk Factors: We Need to Close the Gap", Gut and Liver, 12(1), pp.1~2 (2018), 거트앤리버 소화기연관학회협의회
- Cristescu R, "Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes", Nat Med, 21, pp.449~456 (2015)